Due to the rarity of the disease, data are lacking on the relationships between AML and most risk factors, and strong connections have not been made through epidemiological studies. Pleco Therapeutics is proud to be focusing on a disease where drug development is highly needed.

Secondary Acute Myeloid Leukaemia occurs more frequently in the elderly AML population than in younger patients and is typically more difficult to treat as it is less responsive to standard chemotherapies.

The cause of AML is unknown; however, several risk factors have been associated with increased chance of developing AML, including, age, male sex, a history of smoking, and exposure to high doses of radiation and cytotoxic chemicals.

Pleco’s team is working strenuously on the development of the PlecoidTM agents to increase the survival rate of patients with AML which is a disease carrying a poor prognosis. September is Blood Cancer Awareness month which is an opportunity for Pleco to talk about the support the company aims to provide to 382,000 patients diagnosed..

World Lung Cancer Day is taking place on the 1st of August 2021, PlecoTherapeutics is taking the opportunity to raise awareness to support patients and their families, especially those affected by Small Cell Lung Cancer (SCLC). Sadly, despite improvements in the treatment of SCLC, the survival rates have not improved significantly over the last 40..

Ivo Timmermans, Pleco’s CEO will be speaking at the Digital Conference Findacure’s annual Drug Repurposing Conference for RareDiseases on the 16th of June 2021. Findacure is a UK charity building the rare disease community to drive research and develop treatments. You can register with the following link: https://www.findacure.org.uk/drug-repo-conference/register/

Pleco Therapeutics’ CEO, Ivo Timmermans will present at the Investment Webinar organized by Ruffena Capital on the Tuesday 8th of June 2021 at 2pm. Ruffena Capital is a corporate finance business, that focuses on advising and raising capital for exceptional, privately held businesses. The business is owned and run by their Partners, who have all..

Pleco Therapeutics aims to extend and enhance the lives of patients through its novel Plecoid therapies that increase the effectiveness of current cancer treatments. This year, AML World Awareness Day is taking place in the midst of the COVID pandemic, the latter has heavily disrupted many aspects of cancer care. Early on in the pandemic,..

Pleco is a proud finalist of Global Investor Forum 2021! Do you want to see us in the finale on 15 April during Innovation for Health? Then, secure your ticket now for Innovation for Health via www.hyphenprojects.nl/i4h, join the finale on 15 April! We look forward to seeing you at the online edition of Innovation..

Pleco Therapeutics is a proud semi-finalist of Global Investor Forum 2021! Do you want to see us at the finale on 15 April during Innovation for Health and help us win the AXON Innovation for Health Award? Then, secure your ticket now for Innovation for Health via www.hyphenprojects.nl/i4h, join the semi-finale on 8 April and..